How will the new rules released for the Colorado marijuana industry affect consumers?
Changes to the rules governing Colorado's marijuana industry go into effect Jan. 1, including a groundbreaking path for in-state cannabis research.
All Stories
DEA finalizing Schedule II status for synthetic THC drug Syndros
The DEA is expected to finalize on Wednesday the previously suggested Schedule II status for Syndros, the FDA-approved drug developed by Insys Therapeutics.
MassRoots founder initiates proxy battle to overthrow Denver marijuana firm’s board, leadership
"I strongly believe that the board must be reconstituted to ensure that the interests of the shareholders are appropriately represented," Dietrich wrote in the SEC filing made Monday.
Denver-based cannabis tech firm MassRoots sues founder, alleging “serious misconduct”
The firm fired its CEO for alleged 'serious misconduct' including claims of sex, drugs and misuse of funds, according to a new lawsuit obtained by The Cannabist.
Colorado’s Organa teams up with cannabis firms Canopy Growth and Green House on joint venture in Canada
Three well-known players in the cannabis industry have partnered in the operation of an Ontario indoor cultivation facility, a site they say could serve as a springboard for international expansion.
Denver-based cannabiz MassRoots: “right team and right plan” in place for growth
New CEO Scott Kveton expressed optimism that the company would be able to continue operating beyond the current quarter during a conference call with investors.
Gardner to co-sponsor federal bill to let canna-businesses take tax deductions
Senator Cory Gardner, a Republican from Colorado, is backing federal legislation that would allow state-legal marijuana businesses to claim tax deductions.
Denver-based MassRoots quarterly revenue tanks
The company will need to raise at least $2.5 million by year's end to continue to fund operations, officials disclosed in a regulatory filing made Tuesday with the SEC.
Colorado marijuana shops maintain $136M pace for third straight month
Colorado marijuana shops sold a little more than $136.6 million in flower, edibles, concentrates and accessories for September 2017, according to The Cannabist's calculations on state tax statistics.
“A significant event”: CBD-based pharmaceutical drug Epidiolex presented to FDA for approval
GW Pharmaceuticals, a.k.a. Greenwich Biosciences, has submitted to the FDA a New Drug Application for Epidiolex, a cannabis-based epilepsy drug with CBD.